Novacyt (FRA:NYZ) Valuation Rank

View and export this data going back to 2018. Start your Free Trial

What is Novacyt Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Novacyt Valuation Rank Related Terms

Thank you for viewing the detailed overview of Novacyt's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Novacyt Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (FRA:NYZ) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

NVYTF:USA NCYT:UK ALNOV:France

Address

13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140

Website

https://www.novacyt.com

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.